<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MEGACE ES- megestrol acetate suspension </strong><br>Atlantic Biologicals Corps<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Megace ES safely and effectively.  See full prescribing information for Megace ES. Megace ES (megestrol acetate, USP) Oral Suspension Initial U.S. Approval: 1993
        <span class="Sup">®</span><span class="Sup">®</span><br><br><span class="Sup">®</span><br>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Megace ES oral suspension is a progestin indicated for the treatment of <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span>, or an unexplained significant <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> in patients with a diagnosis of <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immunodeficiency syndrome</span> (AIDS) .
                                    <span class="Sup">®</span><a href="#inv-b8ab2f84-7962-4e58-a50d-6d5466bf1b41">(1)</a> </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">The recommended adult initial dosage of Megace ES oral suspension is 625 mg/day (5 mL/day or one teaspoon daily). Shake the container well before using .
                                    <span class="Sup">®</span><a href="#inv-c4946e93-0ee6-486a-9f52-dc349da19fec">(2)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Oral suspension containing 125 mg of megestrol acetate per mL .
                                    <a href="#inv-9ca61eba-957a-47ac-9971-154f40f978d6">(3)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>History of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to megestrol acetate or any component of the formulation .
                                        <a href="#inv-589e84fc-753d-4fb4-8e48-1ee84e8b5b2b">(4.1)</a>
</dd>
<dt>•</dt>
<dd>Known or suspected pregnancy .
                                        <a href="#inv-a13589be-c1bb-4fce-b153-c74ab63739ab">(4.2)</a><a href="#inv-b3c13167-f469-4b2e-9e90-85b3c8431156">(8.1)</a>
</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Women of childbearing potential should be advised to avoid becoming pregnant .
                                        <a href="#inv-35db0fdc-a62c-4593-8d27-3fefe0c1e573">(5.2)</a>
</dd>
<dt>•</dt>
<dd>Use with caution in patients with a history of thromboembolic disease .
                                        <a href="#inv-69b1be5d-0ef7-43a6-a0a3-5f02f2413e25">(5.1)</a>
</dd>
<dt>•</dt>
<dd>Clinical cases of overt Cushing's Syndrome have been reported in association with the chronic use of megestrol acetate.  In addition, clinical cases of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> have been observed in patients receiving or being withdrawn from chronic megestrol acetate in the stressed and non-stressed state .
                                        <a href="#ID_797e9f02-359c-4a89-8463-67d301abc9b7">(5.3)</a>
</dd>
<dt>•</dt>
<dd>New onset and exacerbation of pre-existing <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> have been reported .
                                        <a href="#inv-cd4fe590-cbda-4823-9818-67bbff5e0a10">(5.4)</a>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse events occurring in &gt; 5% of all patients receiving 800mg/20mL of megestrol acetate oral suspension in the two clinical efficacy trials were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> .
                                    <a href="#inv-70973f44-33ca-47fa-aefd-705d979a3f9b">(6.2)</a> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Par Pharmaceutical, Inc. at 1-800-828-9393, option 3 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Due to a significant decrease in indinavir exposure, administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate ( , ).
                                    <a href="#inv-b944d7bd-d030-4c63-909d-59112db11247">7.1</a><a href="#inv-b382d8aa-f4b6-453f-8460-a084dc9de659">12.3</a> </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>: In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other therapy .
                                        <span class="Bold">Geriatrics</span><a href="#inv-0f8fa9d2-91cf-4b0e-9751-3b50d02f3484">(8.5)</a>
</dd>
<dt>•</dt>
<dd>: Because of the potential for adverse effects on the newborn, nursing should be discontinued if Megace ES oral suspension is required (8.3).
                                        <span class="Bold">Nursing Mothers</span><span class="Sup">®</span>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 8/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Limitations of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span></a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Pregnancy</a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 General</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Fetal Effects</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal Insufficiency</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Diabetics</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Serious and Otherwise Important Adverse Reactions</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Clinical Trial Experience</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Indinavir</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Zidovudine and Rifabutin</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Use in Women</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis and Mutagenesis and Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Pharmacology and/or Toxicology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-14.2" class="toc">16.2 Storage</a></h2>
<h2><a href="#section-14.3" class="toc">16.3 Safe Handling</a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="inv-b8ab2f84-7962-4e58-a50d-6d5466bf1b41"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<dl>
<dt> </dt>
<dd>Megace ES oral suspension is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span>, or an unexplained significant <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> in patients with a diagnosis of <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immunodeficiency syndrome</span> (AIDS).
                                <span class="Sup">®</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-16501d59-78fb-41fa-8519-05ea2aef8d79"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Limitations of Use</h2>
<p class="First"><span class="Bold">Other Treatable Causes</span></p>
<dl>
<dt> </dt>
<dd>Therapy with megestrol acetate for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> should only be instituted after treatable causes of <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> are sought and addressed. These treatable causes include possible malignancies, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span> affecting absorption, endocrine disease, <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> or psychiatric diseases.
                                        </dd>
</dl>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Use</span></p>
<dl>
<dt> </dt>
<dd>Megestrol acetate is not intended for <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use to avoid <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>.
                                        </dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="inv-c4946e93-0ee6-486a-9f52-dc349da19fec"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended adult initial dosage of Megace ES oral suspension is 625 mg/day (5 mL/day or one teaspoon daily). Shake the container well before using.
                            <span class="Sup">®</span></p>
<p>This strength (125 mg/mL) is not substitutable with other strengths (e.g., 40 mg/mL).  Refer to the prescribing information of the 40 mg/mL product for dosage recommendations for the 40 mg/mL strength.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="inv-9ca61eba-957a-47ac-9971-154f40f978d6"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Megace ES is a milky white, lemon-lime flavored oral suspension containing 125 mg of megestrol acetate per mL. Megace ES does not contain the same amount of megestrol acetate as Megace oral suspension or any of the other megestrol acetate oral suspensions
                            <span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Italics">(2).</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="inv-ce63427c-5d03-47f8-91c0-3f293a8f0a2a"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-589e84fc-753d-4fb4-8e48-1ee84e8b5b2b"></a><a name="section-4.1"></a><p></p>
<h2>4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span></h2>
<dl>
<dt> </dt>
<dd>History of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to megestrol acetate or any component of the formulation.
                                        </dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-a13589be-c1bb-4fce-b153-c74ab63739ab"></a><a name="section-4.2"></a><p></p>
<h2>4.2 Pregnancy</h2>
<dl>
<dt> </dt>
<dd>Known or suspected pregnancy.
                                        </dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="inv-1e8b2078-1d8e-4cac-bc0c-beaefb75425a"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-69b1be5d-0ef7-43a6-a0a3-5f02f2413e25"></a><a name="section-5.1"></a><p></p>
<h2>5.1 General</h2>
<dl>
<dt>•</dt>
<dd>Effects on HIV viral replication have not been determined.
                                        </dd>
<dt>•</dt>
<dd>Use with caution in patients with a history of thromboembolic disease.
                                        </dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-35db0fdc-a62c-4593-8d27-3fefe0c1e573"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Fetal Effects</h2>
<p class="First">Megestrol acetate may cause fetal harm when administered to a pregnant woman. For animal data on fetal effects, see There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking (receiving) this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.
                                    <span class="Italics">NonClinical Toxicology: Impairment of Fertility (13.1).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_797e9f02-359c-4a89-8463-67d301abc9b7"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal Insufficiency</span></h2>
<dl>
<dt> </dt>
<dd>The glucocorticoid activity of megestrol acetate oral suspension has not been fully evaluated. Clinical cases of overt Cushing's Syndrome have been reported in association with the chronic use of megestrol acetate. In addition, clinical cases of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> have been observed in patients receiving or being withdrawn from chronic megestrol acetate therapy in the stressed and non-stressed state. Furthermore, adrenocorticotropin (ACTH) stimulation testing has revealed the frequent occurrence of asymptomatic pituitary-adrenal suppression in patients treated with chronic megestrol acetate therapy. Therefore, the possibility of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> should be considered in any patient receiving or being withdrawn from chronic Megace ES therapy who presents with symptoms and/or signs suggestive of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span> (e.g., <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>) in either the stressed or non-stressed state. Laboratory evaluation for <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> and consideration of replacement or stress doses of a rapidly acting glucocorticoid are strongly recommended in such patients. Failure to recognize inhibition of the hypothalamic-pituitary adrenal axis may result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Finally, in patients who are receiving or being withdrawn from chronic Megace ES therapy, consideration should be given to the use of empiric therapy with stress doses of a rapidly acting glucocorticoid during stress or serious intercurrent illness (e.g., surgery, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>).
                                        <span class="Sup">®</span><span class="Sup">®</span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-cd4fe590-cbda-4823-9818-67bbff5e0a10"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Diabetics</h2>
<dl>
<dt> </dt>
<dd>Clinical cases of new onset <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and exacerbation of pre-existing <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus have been reported in association with the chronic use of megestrol acetate.
                                        </dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="inv-30ce5dfd-5b87-4b75-9c62-15bb3a8564d0"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-f1926338-fa21-4e2b-a00e-e99c53482df5"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Serious and Otherwise Important Adverse Reactions</h2>
<dl>
<dt> </dt>
<dd>The following serious reactions and otherwise important adverse drug reactions are discussed in greater detail in other sections of the labeling:
                                        </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
                                        <span class="Italics">[see Contraindications (4.1)]</span>
</dd>
<dt>•</dt>
<dd>Pregnancy
                                        <span class="Italics">[see Contraindications (4.2)]</span>
</dd>
<dt>•</dt>
<dd>Fetal Effects
                                        <span class="Italics">[see Warnings and Precautions (5.2)]</span>
</dd>
<dt>•</dt>
<dd>Thromboembolic Disease
                                        <span class="Italics">[see Warnings and Precautions (5.1)]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal Insufficiency</span>
                                        <span class="Italics">[see Warnings and Precautions (5.3)]</span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-70973f44-33ca-47fa-aefd-705d979a3f9b"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Clinical Trial Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reactions observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The safety of Megace ES (megestrol acetate oral suspension, 125 mg/mL) was based on three studies of megestrol acetate oral suspension (40 mg/mL).  The adverse reaction profile of these 3 studies are presented below.
                                    <span class="Sup">®</span></p>
<p>Adverse events which occurred in at least 5% of patients in any arm of the two clinical efficacy trials and the open trial for megestrol acetate oral suspension are listed below by treatment group. All patients listed had at least one post baseline visit during the 12 study weeks.</p>
<a name="_Refinv-f4a026aa-a8d2-4789-99d6-ce02a8e6"></a><table>
<caption><span>Table 1: Adverse Events</span></caption>
<col width="18%">
<col width="14%">
<col width="11%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="8"><p class="First"><span class="Bold">Percentage of Patients Reporting Adverse Events</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4" valign="middle">
<p class="First">Trial 1</p>
<p>(N=236)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle">
<p class="First">Trial 2</p>
<p>(N=87)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">Open Label</p>
<p>Trial</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">
<p class="First">Megestrol</p>
<p>Acetate mg/day</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">100</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">400</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">800</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">800</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1200</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">No. of Patients</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">N=34</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">N=68</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">N=69</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">N=65</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">N=38</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">N=49</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">N=176</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">15</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">14</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">
<p class="First">Libido</p>
<p>Decreased</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary Frequency</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1</p></td>
</tr>
</tbody>
</table>
<p>Adverse events which occurred in 1% to 3% of all patients enrolled in the two clinical efficacy trials with at least one follow-up visit during the first 12 weeks of the study are listed below by body system. Adverse events occurring less than 1% are not included. There were no significant differences between incidence of these events in patients treated with megestrol acetate and patients treated with placebo.</p>
<p><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span> and <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span>
                                    <span class="Bold">Body as a Whole -</span></p>
<p><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> and <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>
                                    <span class="Bold">Cardiovascular System -</span></p>
<p><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">increased salivation</span> and <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral moniliasis</span>
                                    <span class="Bold">Digestive System -</span></p>
<p><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>
                                    <span class="Bold">Hemic and Lymphatic System -</span></p>
<p>LDH increased, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>
                                    <span class="Bold">Metabolic and Nutritional -</span></p>
<p><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span> and <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span>
                                    <span class="Bold">Nervous System -</span></p>
<p><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> and <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disorder</span>
                                    <span class="Bold">Respiratory System -</span></p>
<p><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, herpes, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">vesiculobullous rash</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> and <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span>
                                    <span class="Bold">Skin and Appendages -</span></p>
<p><span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">amblyopia</span>
                                    <span class="Bold">Special Senses -</span></p>
<p><span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> and <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>.
                                    <span class="Bold">Urogenital System -</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-9f3c73dc-8e5e-48de-a8a8-e50612ec9be1"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Postmarketing Experience</h2>
<dl>
<dt> </dt>
<dd>Postmarketing reports associated with megestrol acetate oral suspension include thromboembolic phenomena including <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>; and <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span>
                                        <span class="Italics">[see Warnings and Precautions (5.1,5.4)].</span>
</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="inv-e1b19b85-7e3c-4bb7-bd1b-5e600b17f6c0"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-b944d7bd-d030-4c63-909d-59112db11247"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Indinavir</h2>
<dl>
<dt> </dt>
<dd>Due to the significant decrease in the exposure of indinavir by megestrol acetate, administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate .
                                        <span class="Italics">[See Clinical Pharmacology (12.3)]</span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-651eb75f-16f1-4816-9732-5e64bb0fbe35"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Zidovudine and Rifabutin</h2>
<dl>
<dt> </dt>
<dd>No dosage adjustment for zidovudine and rifabutin is needed when megestrol acetate is coadministered with these drugs .
                                        <span class="Italics">[See Clinical Pharmacology (12.3)]</span>
</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="inv-f6bdb71f-f257-4098-adb5-ec08bb478fe4"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="inv-b3c13167-f469-4b2e-9e90-85b3c8431156"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<dl>
<dt> </dt>
<dd>Pregnancy Category X No adequate animal teratology information is available at clinically relevant doses. Pregnant rats treated with low doses of megestrol acetate (0.02-fold the recommended clinical dose) resulted in a reduction in fetal weight and number of live births, and <span class="product-label-link" type="condition" conceptid="4140373" conceptname="Feminized male">feminization</span> of male fetuses.
                                        <span class="Italics">[see Warnings and Precautions (5.2)].</span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="inv-3ac02054-aa5d-4db1-b39b-c16a705b1969"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<dl>
<dt> </dt>
<dd>Because of the potential for adverse effects on the newborn, nursing should be discontinued if Megace ES oral suspension is required.
                                        <span class="Sup">®</span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="inv-7398d2b6-a4f0-4f31-bbdd-c9274e0f5fe7"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<dl>
<dt> </dt>
<dd>Safety and effectiveness in pediatric patients have not been established.
                                        </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="inv-0f8fa9d2-91cf-4b0e-9751-3b50d02f3484"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<dl>
<dt> </dt>
<dd>Clinical studies of megestrol acetate oral suspension in the treatment of <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span>, or an unexplained significant <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> in patients with AIDS did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently than younger patients. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
                                        </dd>
</dl>
<p class="First">Megestrol acetate is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-f152647a-532c-4e70-a8ce-06908a8be6fa"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Use in Women</h2>
<p class="First">Megestrol acetate has had limited use in HIV infected women.</p>
<p>All 10 women in the clinical trials reported breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Megace ES is a progesterone derivative, which may induce <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> in women.
                                    <span class="Sup">®</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="inv-ca4715d5-d84a-4b76-85e3-7878efc9dfaa"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<dl>
<dt> </dt>
<dd>No serious unexpected side effects have resulted from studies involving megestrol acetate oral suspension administered in dosages as high as 1200 mg/day. In post-marketing experience, limited reports of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> have been received.  Signs and symptoms reported in the context of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> included <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">unsteady gait</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">listlessness</span>, and <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>.  There is no specific antidote for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with Megace ES oral suspension.  In case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, appropriate supportive measures should be taken.  Megestrol acetate has not been tested for dialyzability; however, due to its low solubility it is postulated that dialysis would not be an effective means of treating <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.
                                <span class="Sup">®</span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="inv-5d537588-9fd0-497b-8ec5-2960be0a5a4a"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<dl>
<dt> </dt>
<dd>Megace ES oral suspension contains megestrol acetate, a synthetic derivative of the naturally occurring steroid hormone, progesterone. Megestrol acetate is a white, crystalline solid chemically designated as 17-Hydroxy-6-methyl pregna-4,6-diene-3,20-dione acetate. Solubility at 37° C in water is 2 mcg per mL, solubility in plasma is 24 mcg per mL. Its molecular weight is 384.52.
                                <span class="Sup">®</span>
</dd>
<dt> </dt>
<dd>The chemical formula is C H O and the structural formula is represented as follows:
                                <span class="Sub">24</span><span class="Sub">32</span><span class="Sub">4</span>
</dd>
</dl>
<div class="Figure">
<a name="id1799247"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=654854bc-f847-4e3b-a0a1-8716553460ac&amp;name=ad5147c4-60e0-442f-b4fd-41d1956d7724-01.jpg">
</div>
<p class="First"><span class="Bold">Figure 1: Megestrol Acetate Chemical Structure</span></p>
<p>Megace ES is an oral suspension containing 125 mg of megestrol acetate per mL.
                            <span class="Sup">®</span></p>
<p>Megace ES oral suspension contains the following inactive ingredients: alcohol (max 0.06% v/v from flavor), artificial lime flavor, citric acid monohydrate, docusate sodium, hydroxypropyl methylcellulose (hypromellose), natural and artificial lemon flavor, purified water, sodium benzoate, sodium citrate dihydrate, and sucrose.
                            <span class="Sup">®</span></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="inv-1b8fcf1b-eddf-470b-800f-1493412a9704"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="inv-91e6ec34-7343-48ff-b56a-0f5dea562d88"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Several investigators have reported on the appetite enhancing property of megestrol acetate and its possible use in <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span>. The precise mechanism by which megestrol acetate produces effects in <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> and <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span> is unknown at the present time.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="inv-b382d8aa-f4b6-453f-8460-a084dc9de659"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-6382ee33-2084-4e96-9d4b-631abd7b4be0"></a><a name="section-11.2.1"></a><p></p>
<h3><span class="Italics">Absorption and Distribution</span></h3>
<dl>
<dt> </dt>
<dd>Mean plasma concentrations of megestrol acetate after administration of 625 mg (125 mg/mL) of Megace ES oral suspension are equivalent under fed conditions to 800 mg (40 mg/mL) of megestrol acetate oral suspension in healthy volunteers.
                                                <span class="Sup">®</span>
</dd>
<dt> </dt>
<dd>In order to characterize the dose proportionality of Megace ES, pharmacokinetic studies across a range of doses were conducted when administered under fasting and fed conditions. Pharmacokinetics of megestrol acetate was linear in the dosing range between 150 mg and 675 mg after Megace ES administration regardless of meal condition. The mean peak plasma concentration (C ) and the mean area under the concentration time-curve (AUC) after a high fat meal were increased by 48% and 36%, respectively, compared to those under the fasting condition after 625 mg Megace ES administration. This food effect is less than that seen for the original formulation, megestrol acetate 800 mg/20 mL, where a high fat meal significantly increased AUC and C of megestrol acetate to 2-fold and 7-fold, respectively, compared to those under the fasting condition. There was no difference in safety following administration in the fed state, therefore Megace ES could be taken without regard to meals.
                                                <span class="Sup">®</span><span class="Sup">®</span><span class="Sub">max</span><span class="Sup">®</span><span class="Sub">max</span><span class="Sup">®</span>
</dd>
<dt> </dt>
<dd>Plasma steady state pharmacokinetics of megestrol acetate was evaluated in 10 adult, cachectic male adult patients with <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immunodeficiency syndrome</span> (AIDS) and an involuntary <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> greater than 10% of baseline who received single oral doses of 800 mg/day of megestrol acetate oral suspension for 21 days. The Mean (±1SD) C of megestrol acetate was 753 (±539) ng/mL. The mean AUC was 10476 (±7788) ng x hr/mL. Median T value was five hours.
                                                <span class="Sub">max</span><span class="Sub">max</span>
</dd>
<dt> </dt>
<dd>In another study, 24 asymptomatic HIV seropositive male adult subjects were dosed once daily with 750 mg of megestrol acetate oral suspension for 14 days. Mean C and AUC values were 490 (±238) ng/mL and 6779 (±3048) hr x ng/mL, respectively. The median T value was three hours. The mean C value was 202 (±101) ng/mL. The mean % of fluctuation value was 107 (±40).
                                                <span class="Sub">max</span><span class="Sub">max</span><span class="Sub">min</span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-3303bd59-d7b0-4ae1-a7c3-b75951e964f5"></a><a name="section-11.2.2"></a><p></p>
<h3><span class="Italics">Metabolism and Excretion</span></h3>
<dl>
<dt> </dt>
<dd>The major route of drug elimination in humans is urine. When radio-labeled megestrol acetate was administered to humans in doses of 4 to 90 mg, the urinary excretion within 10 days ranged from 56.5% to 78.4% (mean 66.4%) and fecal excretion ranged from 7.7% to 30.3% (mean 19.8%). The total recovered radioactivity varied between 83.1% and 94.7% (mean 86.2%).
                                                </dd>
<dt> </dt>
<dd>Megestrol acetate metabolites which were identified in urine constituted 5% to 8% of the dose administered. Respiratory excretion as labeled <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> and fat storage may have accounted for at least part of the radioactivity not found in urine and feces.
                                                </dd>
<dt> </dt>
<dd>The mean elimination half-life of megestrol ranged from 20 to 50 hours in healthy subjects.
                                                </dd>
<dt> </dt>
<dd>Specific Populations
                                                </dd>
<dt> </dt>
<dd>The pharmacokinetics of megestrol acetate has not been studied in specific population, for example, pediatric, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.
                                                </dd>
<dt> </dt>
<dd><span class="Bold"><span class="Underline">Drug Interactions</span></span></dd>
<dt> </dt>
<dd>The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.
                                                </dd>
<dt> </dt>
<dd>Zidovudine
                                                </dd>
<dt> </dt>
<dd>Pharmacokinetic studies show that there are no significant alterations in exposure of zidovudine when megestrol acetate is administered with this drug.
                                                </dd>
<dt> </dt>
<dd>Rifabutin
                                                </dd>
<dt> </dt>
<dd>Pharmacokinetic studies show that there are no significant alterations in exposure of rifabutin when megestrol acetate is administered with this drug.
                                                </dd>
<dt> </dt>
<dd>Indinavir
                                                </dd>
<dt> </dt>
<dd>A pharmacokinetic study in healthy male subjects demonstrated that coadministration of megestrol acetate (675 mg for 14 days) and indinavir (single dose 800 mg) results in a significant decrease in the pharmacokinetic parameters (~32% for C and ~21% for AUC) of indinavir.
                                                <span class="Sub">max</span>
</dd>
</dl>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="inv-648ec754-1224-421a-9dcc-011001449907"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="inv-51077c21-c85f-4d04-8244-b7ab743bd95d"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis and Mutagenesis and Impairment of Fertility</h2>
<dl>
<dt> </dt>
<dd>Data on carcinogenesis were obtained from studies conducted in dogs, monkeys and rats treated with megestrol acetate at doses up to 0.01 to 0.1-fold the recommended clinical dose (13.3 mg/kg/day) based on body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>. No males were used in the dog and monkey studies. In female beagles, megestrol acetate (0.01, 0.1 or 0.25 mg/kg/day) administered for up to 7 years induced both benign and <span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">malignant tumors</span> of the breast. In female monkeys, no tumors were found following 10 years of treatment with 0.01, 0.1 or 0.5 mg/kg/day megestrol acetate. Pituitary tumors were observed in female rats treated with 3.9 or 10 mg/kg/day of megestrol acetate for 2 years. The relationship of these tumors in rats and dogs to humans is unknown but should be considered in assessing the risk-to-benefit ratio when prescribing Megace ES oral suspension and in surveillance of patients on therapy.
                                        <span class="Sup">®</span>
</dd>
<dt> </dt>
<dd>Megestrol acetate induced unscheduled DNA synthesis in primary cultures of human hepatocytes, but not in rat hepatocytes. Megestrol administered to mice increased the frequency of sister chromatid exchange and chromosomal aberrations in bone marrow cells after single intraperitonial doses of 16.25 and 32.50 mg/kg. Perinatal/postnatal (segment III) toxicity studies were performed in rats at doses up to 0.02 -fold the recommended clinical dose (13.3 mg/kg/day) based on body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>. In these low dose studies, the reproductive capability of male offspring of megestrol acetate-treated females was impaired. Similar results were obtained in dogs. No toxicity data are currently available on male reproduction (spermatogenesis)
                                        <span class="Italics">[see Warnings and Precautions (5.2)].</span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="inv-8e9be6c8-25e9-4405-a053-56f1a0f124bd"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Pharmacology and/or Toxicology</h2>
<dl>
<dt> </dt>
<dd>Long-term treatment with Megace ES may increase the risk of <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infections</span>. A trend toward increased frequency of <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infections</span>, decreased lymphocyte counts and increased neutrophil counts was observed in a two-year chronic toxicity/carcinogenicity study of megestrol acetate conducted in rats.
                                        <span class="Sup">®</span>
</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="inv-aa55b71d-aa0f-4c68-9c32-d11f8815ad84"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<dl>
<dt> </dt>
<dd>The efficacy of Megace ES (megestrol acetate oral suspension, 125 mg/mL) was based on two trials of megestrol acetate oral suspension (40 mg/mL).  These two trials are described below.
                                <span class="Sup">®</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-93adb6b0-5f4b-49fa-a18a-b105cd8d7fa0"></a><a name="section-13.1"></a><p></p>
<p class="First"><span class="Bold">Trial 1</span></p>
<dl>
<dt> </dt>
<dd>One was a multicenter, randomized, double-blind, placebo-controlled study comparing megestrol acetate (MA) at doses of 100 mg, 400 mg, and 800 mg per day versus placebo in AIDS patients with <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>/<span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span> and significant <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. Of the 270 patients entered on study, 195 met all inclusion/exclusion criteria, had at least two additional post baseline weight measurements over a 12 week period or had one post baseline weight measurement but dropped out for therapeutic failure. The percent of patients gaining 2.3 kg or more at maximum <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> in 12 study weeks was statistically significantly greater for the 800 mg (64%) and 400 mg (57%) MA-treated groups than for the placebo group (24%). Mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span> from baseline to last evaluation in 12 study weeks in the 800 mg MA-treated group by 3.5 kg, the 400 mg MA group by 1.9 kg, the 100 mg MA group by 0.9 kg and decreased in the placebo group by 0.7 kg. Mean weight changes at 4, 8 and 12 weeks for patients evaluable for efficacy in the two clinical trials is shown graphically. Changes in body composition during the 12 study weeks as measured by bioelectrical impedance analysis showed increases in non-water body weight in the MA-treated groups. In addition, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> developed or worsened in only 3 patients.
                                        </dd>
<dt> </dt>
<dd>Greater percentages of MA-treated patients in the 800 mg group (89%), the 400 mg group (68%) and the 100 mg group (72%), than in the placebo group (50%), showed an improvement in appetite at last evaluation during the 12 study weeks. A statistically significant difference was observed between the 800 mg MA-treated group and the placebo group in the change in caloric intake from baseline to time of maximum weight change. Patients were asked to assess weight change, appetite, appearance, and overall perception of well-being in a 9 question survey. At maximum weight change only the 800 mg MA-treated group gave responses that were statistically significantly more favorable to all questions when compared to the placebo-treated group. A dose response was noted in the survey with positive responses correlating with higher dose for all questions.
                                        </dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-2a46047a-c6e9-4fba-a664-0eb2353270f5"></a><a name="section-13.2"></a><p></p>
<p class="First"><span class="Bold">Trial 2</span></p>
<dl>
<dt> </dt>
<dd>The second trial was a multicenter, randomized, double-blind, placebo-controlled study comparing megestrol acetate 800 mg/day versus placebo in AIDS patients with <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>/<span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span> and significant <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. Of the 100 patients entered on study, 65 met all inclusion/exclusion criteria, had at least two additional post baseline weight measurements over a 12 week period or had one post baseline weight measurement but dropped out for therapeutic failure. Patients in the 800 mg MA-treated group had a statistically significantly larger increase in mean maximum weight change than patients in the placebo group. From baseline to study week 12, mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span> by 5.1 kg in the MA-treated group and decreased 1.0 kg in the placebo group. Changes in body composition as measured by bioelectrical impedance analysis showed increases in non-water weight in the MA-treated group (see Clinical Studies table). No <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> was reported in the MA-treated group. A greater percentage of MA-treated patients (67%) than placebo-treated patients (38%) showed an improvement in appetite at last evaluation during the 12 study weeks; this difference was statistically significant. There were no statistically significant differences between treatment groups in mean caloric change or in daily caloric intake at time to maximum weight change. In the same 9 question survey referenced in the first trial, patients' assessments of weight change, appetite, appearance, and overall perception of well-being showed increases in mean scores in MA-treated patients as compared to the placebo group.
                                        </dd>
<dt> </dt>
<dd>In both trials, patients tolerated the drug well and no statistically significant differences were seen between the treatment groups with regard to laboratory abnormalities, new <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>, lymphocyte counts, T4 counts, T8 counts, or skin reactivity tests
                                        <span class="Italics">[see Adverse Reactions (6)].</span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-01e6c25c-2cef-496b-acdf-5805164a2723"></a><a name="section-13.3"></a><p></p>
<table>
<caption><span>Table 2:  Megestrol Acetate Oral Suspension Clinical Efficacy Trials</span></caption>
<col width="40%">
<col width="10%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="7"><p class="First"><span class="Bold">Megestrol Acetate Oral Suspension Clinical Efficacy Trials</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4">
<p class="First">Trial 1</p>
<p>Study Accrual Dates</p>
<p>11/88 to 12/90</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">
<p class="First">Trial 2</p>
<p>Study Accrual Dates</p>
<p>5/89 to 4/91</p>
</td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Megestrol Acetate, mg/day</p></td>
<td class="Lrule Toprule" align="center"><p class="First">0</p></td>
<td align="center"><p class="First">100</p></td>
<td align="center"><p class="First">400</p></td>
<td class="Rrule Toprule" align="center"><p class="First">800</p></td>
<td class="Lrule Toprule" align="center"><p class="First">0</p></td>
<td class="Rrule Toprule" align="center"><p class="First">800</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>Entered Patients
                                                        </dd>
</dl></td>
<td class="Lrule" align="center"><p class="First">38</p></td>
<td align="center"><p class="First">82</p></td>
<td align="center"><p class="First">75</p></td>
<td class="Rrule" align="center"><p class="First">75</p></td>
<td class="Lrule" align="center"><p class="First">48</p></td>
<td class="Rrule" align="center"><p class="First">52</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>Evaluable Patients
                                                        </dd>
</dl></td>
<td class="Lrule" align="center"><p class="First">28</p></td>
<td align="center"><p class="First">61</p></td>
<td align="center"><p class="First">53</p></td>
<td class="Rrule" align="center"><p class="First">53</p></td>
<td class="Lrule" align="center"><p class="First">29</p></td>
<td class="Rrule" align="center"><p class="First">36</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Mean Change in Weight (kg)</p></td>
<td class="Lrule"></td>
<td></td>
<td></td>
<td class="Rrule"></td>
<td class="Lrule"></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>Baseline to 12 Weeks
                                                        </dd>
</dl></td>
<td class="Lrule" align="center"><p class="First">0.0</p></td>
<td align="center"><p class="First">1.3</p></td>
<td align="center"><p class="First">4.2</p></td>
<td class="Rrule" align="center"><p class="First">4.9</p></td>
<td class="Lrule" align="center"><p class="First">-1.0</p></td>
<td class="Rrule" align="center"><p class="First">5.1</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>% Patients ≥2.3 kg Gain
                                                        </dd>
<dt> </dt>
<dd>at Last Evaluation in 12 Weeks
                                                        </dd>
</dl></td>
<td class="Lrule" align="center" valign="bottom"><p class="First">21</p></td>
<td align="center" valign="bottom"><p class="First">44</p></td>
<td align="center" valign="bottom"><p class="First">57</p></td>
<td class="Rrule" align="center" valign="bottom"><p class="First">64</p></td>
<td class="Lrule" align="center" valign="bottom"><p class="First">28</p></td>
<td class="Rrule" align="center" valign="bottom"><p class="First">47</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>Mean Changes in Body Composition*:
                                                        </dd>
</dl></td>
<td class="Lrule"></td>
<td></td>
<td></td>
<td class="Rrule"></td>
<td class="Lrule"></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>Fat Body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> (kg)
                                                        </dd>
</dl></td>
<td class="Lrule" align="center"><p class="First">0.0</p></td>
<td align="center"><p class="First">1.0</p></td>
<td align="center"><p class="First">1.3</p></td>
<td class="Rrule" align="center"><p class="First">2.5</p></td>
<td class="Lrule" align="center"><p class="First">0.7</p></td>
<td class="Rrule" align="center"><p class="First">2.6</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>Lean Body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> (kg)
                                                        </dd>
</dl></td>
<td class="Lrule" align="center"><p class="First">-0.8</p></td>
<td align="center"><p class="First">-0.1</p></td>
<td align="center"><p class="First">0.7</p></td>
<td class="Rrule" align="center"><p class="First">1.1</p></td>
<td class="Lrule" align="center"><p class="First">-0.7</p></td>
<td class="Rrule" align="center"><p class="First">-0.3</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>Water (liters)
                                                        </dd>
</dl></td>
<td class="Lrule" align="center"><p class="First">-1.3</p></td>
<td align="center"><p class="First">-0.3</p></td>
<td align="center"><p class="First">0.0</p></td>
<td class="Rrule" align="center"><p class="First">0.0</p></td>
<td class="Lrule" align="center"><p class="First">-0.1</p></td>
<td class="Rrule" align="center"><p class="First">-0.1</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>% Patients With Improved Appetite:
                                                        </dd>
</dl></td>
<td class="Lrule"></td>
<td></td>
<td></td>
<td class="Rrule"></td>
<td class="Lrule"></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>At Time of Maximum
                                                        </dd>
</dl></td>
<td class="Lrule"></td>
<td></td>
<td></td>
<td class="Rrule"></td>
<td class="Lrule"></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>Weight Change
                                                        </dd>
</dl></td>
<td class="Lrule" align="center"><p class="First">50</p></td>
<td align="center"><p class="First">72</p></td>
<td align="center"><p class="First">72</p></td>
<td class="Rrule" align="center"><p class="First">93</p></td>
<td class="Lrule" align="center"><p class="First">48</p></td>
<td class="Rrule" align="center"><p class="First">69</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>At Last Evaluation in 12 Weeks
                                                        </dd>
</dl></td>
<td class="Lrule" align="center" valign="bottom"><p class="First">50</p></td>
<td align="center" valign="bottom"><p class="First">72</p></td>
<td align="center" valign="bottom"><p class="First">68</p></td>
<td class="Rrule" align="center" valign="bottom"><p class="First">89</p></td>
<td class="Lrule" align="center" valign="bottom"><p class="First">38</p></td>
<td class="Rrule" align="center" valign="bottom"><p class="First">67</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>Mean Change in Daily Caloric Intake:
                                                        </dd>
</dl></td>
<td class="Lrule"></td>
<td></td>
<td></td>
<td class="Rrule"></td>
<td class="Lrule"></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>Baseline to Time of Maximum
                                                        </dd>
</dl></td>
<td class="Lrule"></td>
<td></td>
<td></td>
<td class="Rrule"></td>
<td class="Lrule"></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>Weight Change
                                                        </dd>
</dl></td>
<td class="Botrule Lrule" align="center"><p class="First">-107</p></td>
<td align="center"><p class="First">326</p></td>
<td align="center"><p class="First">308</p></td>
<td class="Botrule Rrule" align="center"><p class="First">646</p></td>
<td class="Botrule Lrule" align="center"><p class="First">30</p></td>
<td class="Botrule Rrule" align="center"><p class="First">464</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" colspan="7"><p class="First">*Based on bioelectrical impedance analysis determinations at last evaluation in 12 weeks.</p></td></tr>
</tbody>
</table>
<div class="Figure">
<a name="id4339253"></a><img alt="Figure 2: Mean Weight Change for Patients Evaluable for Efficacy" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=654854bc-f847-4e3b-a0a1-8716553460ac&amp;name=ad5147c4-60e0-442f-b4fd-41d1956d7724-02.jpg">
</div>
<p class="First"><span class="Bold">Figure 2: Mean Weight Change for Patients Evaluable for Efficacy in Trial 1</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-f54da346-f7e2-4f59-a62f-f6d7aca63e78"></a><a name="section-13.4"></a><p></p>
<div class="Figure">
<a name="id4339259"></a><img alt="Figure 3: Mean Weight Change for Patients Evaluable for Efficacy in Trial 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=654854bc-f847-4e3b-a0a1-8716553460ac&amp;name=ad5147c4-60e0-442f-b4fd-41d1956d7724-03.jpg">
</div>
<p class="First"><span class="Bold">Figure 3: Mean Weight Change for Patients Evaluable for Efficacy in Trial 2</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_fafb0e18-e0a5-4231-8cb5-3f0a032995c9"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">NDC:17856-0949-5 in a CUP of 5 SUSPENSIONS</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cd2abc87-454c-41cf-9f2a-2692fbfa76d5"></a><a name="section-14.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<dl>
<dt> </dt>
<dd>Megace ES oral suspension is a milky white, lemon-lime flavored oral suspension containing 125 mg of megestrol acetate per mL.  Available in bottles of 150 mL (5 fl oz) NDC 49884-949-69.
                                        <span class="Sup">®</span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_42c5b01e-bbe7-4b02-90a7-0ef4fe462a15"></a><a name="section-14.2"></a><p></p>
<h2>16.2 Storage</h2>
<dl>
<dt> </dt>
<dd>Store Megace ES oral suspension between 15° to 25° C (59° to 77° F) and dispense in a tight container.  Protect from heat.
                                        <span class="Sup">®</span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a4cc2e84-723d-4842-8c5b-d0a4890e74ab"></a><a name="section-14.3"></a><p></p>
<h2>16.3 Safe Handling</h2>
<p class="First"><span class="Bold">Health Hazard Data</span></p>
<dl>
<dt> </dt>
<dd>There is no threshold limit value established by OSHA, NIOSH, or ACGIH. Exposure or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> at levels approaching recommended dosing levels could result in side effects described above Women at risk of pregnancy should avoid such exposure.
                                        <span class="Italics">[see Warnings and Precautions (5) and Adverse Reactions (6)].</span>
</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="inv-f123b6e6-539b-4da9-9be7-b22a62ae9f70"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<dl>
<dt> </dt>
<dd><span class="Bold">The prescriber should inform the patient about the product differences to avoid overdosing or underdosing of megestrol acetate. The recommended adult dosage of Megace ES is one teaspoon (5 mL) once a day
                                    <span class="Sup">®</span><span class="Italics">[see table in Dosage and Administration (2)].</span></span></dd>
<dt> </dt>
<dd>Patients using Megace ES should receive the following instructions:
                                <span class="Sup">®</span>
</dd>
<dt>•</dt>
<dd>This medication is to be used as directed by the physician.
                                </dd>
<dt>•</dt>
<dd>Megace ES (625 mg/5 mL) does not contain the same amount of megestrol acetate as Megace oral suspension or any of the other megestrol acetate oral suspensions. Megace ES contains 625 mg of megestrol acetate per 5 mL (125mg/mL) whereas Megace oral suspension and other megestrol acetate oral suspensions contain 800 mg per 20 mL (40 mg/mL).
                                <span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span>
</dd>
<dt>•</dt>
<dd>Report any adverse reaction experiences while taking this medication.
                                </dd>
<dt>•</dt>
<dd>Use contraception while taking this medication if you are a woman capable of becoming pregnant.
                                </dd>
<dt>•</dt>
<dd>Notify your physician if you become pregnant while taking this medication.
                                </dd>
</dl>
<p class="First">Manufactured by:</p>
<p><span class="Bold">PAR PHARMACEUTICAL COMPANIES, INC.</span></p>
<p>Spring Valley, New York 10977</p>
<p>U.S. Patent No.:</p>
<dl>
<dt> </dt>
<dd>6,592,903
                                </dd>
<dt> </dt>
<dd>7,101,576
                                </dd>
</dl>
<p>Revised: 03/14     OS949-01-1-09</p>
<p>Megace® is a registered trademark of Bristol-Myers Squibb Company licensed to Par Pharmaceutical, Inc.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_daaa5418-6d38-4173-b04e-5583ddf4d9de"></a><a name="section-16"></a><p></p>
<h1>MEGACE ES (MEGESTEROL ACETATE) SUSPENSION</h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=654854bc-f847-4e3b-a0a1-8716553460ac&amp;name=rspl17856-0949.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MEGACE ES 		
					</strong><br><span class="contentTableReg">megesterol acetate suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:17856-0949(NDC:49884-949)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MEGESTROL ACETATE</strong> (MEGESTROL) </td>
<td class="formItem">MEGESTROL ACETATE</td>
<td class="formItem">125 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DOCUSATE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRISODIUM CITRATE DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LEMON</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LIME (CITRUS)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2208 (100 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">LEMON, LIME</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17856-0949-5</td>
<td class="formItem">5 mL in 1 CUP</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021778</td>
<td class="formItem">07/02/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Atlantic Biologicals Corps
							(047437707)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Atlantic Biologicals Corps (047437707)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Atlantic Biologicals Corps</td>
<td class="formItem"></td>
<td class="formItem">047437707</td>
<td class="formItem">RELABEL(17856-0949), REPACK(17856-0949)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bcb4eb8f-40da-47b5-9061-dbc973467acb</div>
<div>Set id: 654854bc-f847-4e3b-a0a1-8716553460ac</div>
<div>Version: 3</div>
<div>Effective Time: 20140318</div>
</div>
</div> <div class="DistributorName">Atlantic Biologicals Corps</div></p>
</body></html>
